Scarica l'app Stockscreener
9.00
3.33%
-0.31
Lyra Therapeutics Inc Borsa (LYRA) Ultime notizie
Lyra Therapeutics: Regulatory Pathway For Non-Polyp Patients, An Underappreciated Catalyst - Seeking Alpha
Lyra Therapeutics, Inc. (NASDAQ:LYRA) Stake Lessened by Two Sigma Investments LP - Defense World
HC Wainwright Expects Higher Earnings for Lyra Therapeutics - Defense World
Lyra Therapeutics (LYRA) Upgraded to Buy: Here's Why - sharewise
H.C. Wainwright lifts Lyra Therapeutics stock target to $16 By Investing.com - Investing.com Canada
Lyra Therapeutics (LYRA) Price Target Raised by HC Wainwright & Co. | LYRA Stock News - GuruFocus
H.C. Wainwright Ups Target Price for Lyra Therapeutics (LYRA) to $16 | LYRA Stock News - GuruFocus
Lyra Therapeutics, Inc. (NASDAQ:LYRA) Shares Sold by Two Sigma Advisers LP - Defense World
Lyra Stock Soars 356% in a Week on Strong Rhinosinusitis Study Success - MSN
Lyra Eyes US Filing For LYR-210 After Surprise ENLIGHTEN 2 Win - insights.citeline.com
Northern Trust Corp Has $59,000 Stock Position in Lyra Therapeutics, Inc. (NASDAQ:LYRA) - Defense World
Study: LYR-210 Shows Promise in Chronic Rhinosinusitis With Nasal Polyps - Pharmacy Times
BNP Paribas Financial Markets Makes New Investment in Lyra Therapeutics, Inc. (NASDAQ:LYRA) - Defense World
Best Biotech Stocks To Watch Now – June 2nd - Defense World
Biotech Triumphs: Lyra, Vera, And US Gold Shine Bright - Finimize
Lyra Therapeutics stock hits 52-week high at $28.66 By Investing.com - Investing.com Canada
Lyra Therapeutics Stock Skyrockets On Positive Trial Data For Its Nasal Implant: Retail’s Thrilled - Asianet Newsable
Lyra Therapeutics reports positive phase 3 trial results for CRS treatment By Investing.com - Investing.com South Africa
Applied Digital Corp, Meta Platforms, Alphabet, Lyra Therapeutics, Tesla: Why These 5 Stocks Are On Investors' Radars Today - Benzinga
Lyra Therapeutics Stock Skyrockets On Positive Trial Data For Its Nasal Implant: Retail’s Thrilled By Stocktwits - Investing.com India
Redemption for Lyra as second phase III rhinosinusitis trial hits goal - BioWorld MedTech
One year after massive layoffs, Lyra stock soars 400% on trial win - The Business Journals
Lyra Therapeutics (LYRA) Surges 376% on Positive Phase 3 Trial R - GuruFocus
Lyra Therapeutics (LYRA) Surges 376% on Positive Phase 3 Trial Results - GuruFocus
Microcap Lyra Therapeutics surges 376% on phase 3 rhinosinusitis data - Seeking Alpha
Nasdaq Edges Higher; ISM Manufacturing PMI Falls In May - Benzinga
Lyra Therapeutics Shares Climb Over 500% After Major CRS Trial Win - Yahoo Finance
Lyra Therapeutics Spikes 417% as LYR-210 Redefines CRS Therapy - Wall Street Pit
LYR-210 Nasal Implant for CRS Brings Symptom Relief in Phase 3 ENLIGHTEN 2 - HCPLive
Lyra Therapeutics says ENLIGHTEN 2 trial of LYR-210 met primary endpoint - TipRanks
Lyra Therapeutics Soars on Breakthrough Nasal Implant Results - RagingBull
Lyra Therapeutics Shares Soar 603.25% to $34.67 on LYR-210 Trial Success - Trading Pedia
Transcript : Lyra Therapeutics, Inc.Special Call - marketscreener.com
Lyra Therapeutics stock hits 52-week high at $28.66 - Investing.com
This penny stock just spiked 550% in a day; Time to buy? - Finbold
Lyra Therapeutics Stock (LYRA) Rockets 530% on Phase 3 Trial Results - TipRanks
Pre-market Movers: LYRA, INM, OGEN, VERA... - RTTNews
Lyra Therapeutics Reports Positive Results From The Enlighten 2 Phase 3 Trial Of Lyr-210 - MarketScreener
Lyra Says Phase 3 Trial of Nasal Implant for Chronic Rhinosinusitis Meets Endpoints - marketscreener.com
Why Is Lyra Therapeutics Stock Surging Over 400% On Monday? - Benzinga
Lyra Therapeutics Announces Positive Phase 3 Trial Results - TipRanks
LYRA Sees Promising Results in ENLIGHTEN 2 Phase 3 Trial for CRS Treatment | LYRA Stock News - GuruFocus
Lyra Therapeutics reports positive phase 3 trial results for CRS treatment - Investing.com Australia
Why Blueprint Medicines Shares Are Trading Higher By 27%; Here Are 20 Stocks Moving Premarket - Benzinga
Lyra Therapeutics stock soars on positive Phase 3 trial results By Investing.com - Investing.com Canada
Lyra Therapeutics stock soars on positive Phase 3 trial results - Investing.com
Lyra Therapeutics Reports Positive Results from the ENLIGHTEN 2 Phase 3 Trial of LYR-210 Achieving Statistically Significant Results for Primary and Key Secondary Endpoints in the Treatment of Chronic Rhinosinusitis (CRS) - GlobeNewswire
Lyra Therapeutics (NASDAQ:LYRA) Stock Rating Upgraded by Wall Street Zen - Defense World
0.34%
7.69%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):